Snehal Patel Purchases 3,200 Shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI) Stock

Greenwich LifeSciences, Inc. (NASDAQ:GLSI - Get Free Report) CEO Snehal Patel acquired 3,200 shares of the firm's stock in a transaction that occurred on Monday, December 30th. The shares were bought at an average price of $11.12 per share, with a total value of $35,584.00. Following the completion of the purchase, the chief executive officer now directly owns 5,539,302 shares in the company, valued at $61,597,038.24. The trade was a 0.06 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Greenwich LifeSciences Stock Performance

NASDAQ:GLSI traded up $0.51 during midday trading on Thursday, reaching $11.74. 35,380 shares of the stock traded hands, compared to its average volume of 39,041. The stock has a market capitalization of $154.32 million, a PE ratio of -14.67 and a beta of 1.61. Greenwich LifeSciences, Inc. has a 12-month low of $8.00 and a 12-month high of $21.44. The business has a 50-day moving average of $13.25 and a two-hundred day moving average of $14.24.

Institutional Trading of Greenwich LifeSciences

Several hedge funds and other institutional investors have recently made changes to their positions in GLSI. Rhumbline Advisers purchased a new position in shares of Greenwich LifeSciences in the 2nd quarter valued at approximately $117,000. Bank of New York Mellon Corp acquired a new position in Greenwich LifeSciences during the 2nd quarter valued at approximately $264,000. Garden State Investment Advisory Services LLC purchased a new position in shares of Greenwich LifeSciences in the third quarter worth $253,000. Barclays PLC lifted its stake in shares of Greenwich LifeSciences by 323.3% during the third quarter. Barclays PLC now owns 8,560 shares of the company's stock worth $123,000 after buying an additional 6,538 shares during the period. Finally, Geode Capital Management LLC grew its holdings in shares of Greenwich LifeSciences by 4.6% during the third quarter. Geode Capital Management LLC now owns 133,550 shares of the company's stock valued at $1,919,000 after buying an additional 5,861 shares during the last quarter. Hedge funds and other institutional investors own 4.16% of the company's stock.

About Greenwich LifeSciences

Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, develops novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.